SlideShare a Scribd company logo
HIMANSHU YADAV (201408006)
M.PHARM (PHARMACOLOGY)
SGT UNIVERSITY
Skin sensitization
toxicity studies
Introduction
 OECD Guidelines for Testing of Chemicals are
periodically reviewed in light of scientific progress.
This updated version of the original guideline 406,
adopted in 1981, is the outcome of a meeting of
OECD experts held in Paris in May 1991.
 In updated version (17 Jul 1992) preference given to
the guinea pig as an animal of choice for predictive
sensitization tests for several decades.
Types of Test
Two types of tests have been developed:
1. Adjuvant tests in which sensitization is potentiated
by the injection of Freunds Complete Adjuvant
(FCA).
2. Non-adjuvant tests
Types of Test
 In the original guideline 406, 4 adjuvant tests and 3
non-adjuvant tests were considered.
 In updated version, the Guinea Pig Maximization
Test (GPMT) of Magnusson and Kligman which uses
adjuvant (1)(2)(3)(4) and the non-adjuvant Buehler
Test (5)(6) are given preference over other methods.
Types of Test
 Immune system of the mouse has been investigated
more extensively than that of the guinea pig.
 Advantages: short duration and minimal animal
treatment
 The mouse ear swelling test (MEST) and the local
lymph node assay (LLNA) appear to be promising
Types of Test
 The LLNA or the MEST can be used as a first stage
in the assessment of skin sensitization potential.
 If a positive result is seen, a test substance may be
designated as a potential sensitizer, and it may not
be necessary to conduct a further guinea pig test.
 If a negative result is seen in these test, a guinea pig
test must be conducted.
GENERAL PRINCIPLE OF SENSITISATION
TESTS IN GUINEA PIGS
 The test animals are initially exposed to the test
substance by intradermal injection and/or epidermal
application (induction exposure).
 Following a rest period of 10 to 14 days (induction
period), during which an immune response may develop,
the animals are exposed to a challenge dose.
 The extent and degree of skin reaction to the challenge
exposure in the test animals is compared with that
demonstrated by control animals which undergo sham
treatment during induction and receive the challenge
exposure
ELEMENTS COMMON TO SENSITISATION
TESTS IN GUINEA PIGS
Sex of animals-Healthy Male /female .Females should be
non-pregnant.
Housing and feeding conditions
 Temperature = 20 C (+ 3o C)
 Relative humidity= 30-70%
 Lighting is artificial= 12 hours light, 12 hours dark
 Feeding= conventional diets with an unlimited drinking
water.
 It is essential that guinea pigs receive an adequate
amount of ascorbic acid.
Preparation of the animals
 Acclimatization
 Randomization
 Assignment to the treatment groups
 Clipping, shaving, chemical depilation
 Weighing before the test commence
Reliability check
 Sensitivity of technique used should be assessed
every six months by use of substances which are
known to have mild-to-moderate skin sensitization
properties
A response of :
 30% in an adjuvant test
 15% in a non-adjuvant test should be expected for
mild/moderate sensitizers
 Preferred substances are hexyl cinnamic aldehyde
(CAS No. 101-86-0), mercaptobenzothiazole (CAS
No. 149-30-4) and benzocaine (CAS No. 94-09-7).
Removal of the test substance
 This should be achieved using water or an
appropriate solvent without altering the existing
response or the integrity of the epidermis
GUINEA-PIG MAXIMISATION TEST METHOD
Number of animals
 Treatment group = Min. 10 animals
 control group = 5 animals
 When it is not possible to conclude that the test
substance is a sensitizer, testing in additional
animals to give a total of at least 20 test and 10
control animals is strongly recommended.
Dose levels
 The conc. of test substance used for each induction
exposure should be well-tolerated systemically and
should be the highest to cause mild-to-moderate skin
irritation.
 The conc. used for the challenge exposure should
be the highest non-irritant dose.
 The appropriate conc. can be determined from a
pilot study using 2 or 3 animals. Consideration
should be given to the use of FCA-treated animals
for this purpose
Induction: Intradermal Injections
Day 0 - treated group
 3 pairs of intradermal injections of 0.1 ml volume are
given in the shoulder region which is cleared of hair
so that one of each pair lies on each side of the
midline.
Induction: Intradermal Injections
Day 0 - treated group
Injection 1: a 1:1 mixture (v/v) FCA/water or physiological saline
Injection 2: the test substance in an appropriate vehicle at the selected
concentration
Injection 3: the test substance at the selected concentration formulated
in a 1:1 mixture (v/v) FCA/water or physiological saline.
Induction: Intradermal Injections
 In injection 3, water soluble substances are
dissolved in the aqueous phase prior to mixing with
FCA.
 Liposoluble or insoluble substances are suspended
in FCA prior to combining with the aqueous phase.
 The concentration of test substance shall be equal to
that used in injection 2.
 Injections 1 and 2 are given close to each other and
nearest the head, while 3 is given towards the
caudal part of the test area
Induction: Intradermal Injections
Day 0 - control group
 3 pairs of intradermal injections of 0.1 ml volume are
given in the same sites as in the treated animals.
Induction: Intradermal Injections
Day 0 - control group
Injection 1: a 1:1 mixture (v/v) FCA/water or physiological saline
Injection 2: the undiluted vehicle
Injection 3: a 50% w/v formulation of the vehicle in a 1:1 mixture (v/v)
FCA/water or physiological saline
Induction: Topical Application
Day 5-7 - treated and control groups
 24 hours before the topical induction application –
The test area, after close-clipping or shaving is
painted with 0.5 ml of 10% sodium lauryl sulphate in
vaseline, to create a local irritation (if the substance
is not a skin irritant).
Induction: Topical Application
Day 6-8 - treated group
 The test area is again cleared of hair.
 A filter paper (2 x 4 cm) is fully-loaded with test substance in a
suitable vehicle and applied to the test area for 48 hours.
 The choice of the vehicle should be justified.
 Solids are finely pulverised and incorporated in a suitable
vehicle.
 Liquids can be applied undiluted, if appropriate.
Challenge: Topical Application
Day 20-22 - treated and control groups
 The flanks of treated and control animals are cleared
of hair.
 A patch with the test substance is applied to one
flank of the animals and, a patch with the vehicle
only may also be applied to the other flank.
 The patches are held in contact by an occlusive
dressing for 24 hours.
Observations - treated and control groups
 Remove the patch after 21 hrs, the challenge area is
cleaned and closely-clipped or shaved.
 3 hours later (48 hours from the start of the
challenge application) the skin reaction is observed
 24 hours after this observation a second observation
(72 hours) is made and once again recorded.
 Blind reading of test and control animals is
encouraged
EVALUATION OF CHALLENGE PATCH TEST
REACTIONS
MAGNUSSON AND KLIGMAN GRADING SCALE
 0 = no visible change
 1 = discrete or patchy erythema
 2 = moderate and confluent erythema
 3 = intense erythema and swelling
Rechallenge
 If it is necessary to clarify the results obtained in the
first challenge,
 a second challenge (i.e. a rechallenge), where
appropriate with a new control group, should be
considered approximately one week after the first
one.
 A rechallenge may also be performed on the original
control group.
Clinical observations
 All skin reactions and any unusual findings, including
systemic reactions, resulting from induction and
challenge procedures should be observed and
recorded.
 Other procedures, e.g histopathological
examination, the measurement of skin fold
thickness, may be carried out to clarify doubtful
reactions
THE BUEHLER TEST METHOD
Number of animals
 Treatment group- 20 animals
 Control group- 10 animals
Dose levels
 The conc. of test substance for each induction exposure
should be the highest to cause mild irritation.
 The conc. used for the challenge exposure should be
the highest non-irritating dose.
 The appropriate conc. can be determined from a pilot
study using two or three animals
THE BUEHLER TEST METHOD
 Water soluble test materials- water or a dilute non-
irritating solution of surfactant as the vehicle.
 For other test materials- 80% ethanol/water is
preferred for induction and acetone for challenge
Induction: Topical application
Day 0 - treated group
 One flank is cleared of hair (closely-clipped).
 The test patch system should be fully loaded with
test substance in a suitable vehicle ,held in contact
with the skin for 6 hours.
Induction: Topical application
Day 0 - control group
 One flank is cleared of hair (closely-clipped).
 The vehicle only is applied in a similar manner to
that used for the treated group.
 The test patch system is held in contact with the skin
for 6 hours.
Induction: Topical application
Days 6-8 and 13-15 - treated and control groups
 The same application as on day 0 is carried out on
the same test area (cleared of hair if necessary) of
the same flank on day 6-8, and again on day 13-15
Challenge
Day 27-29 - treated and control groups
 The untreated flank of treated and control animals is
cleared of hair (closely-clipped).
 An occlusive patch of test substance is applied, at the
maximum non-irritant concentration, to the posterior
untreated flank of treated and control animals
 When relevant, an occlusive patch with vehicle only is
also applied to the anterior untreated flank of both
treated and control animals.
 The patches are held in contact by a suitable dressing
for 6 hours.
Observations - treated and control groups
 21 hours after removing the patch the challenge
area is cleared of hair;
 3 hrs later (i.e. 30 hrs after application of the
challenge patch) the skin reactions are observed and
recorded
 24 hours after the 30 hour observation ( 54 hours
after application of the challenge patch) skin
reactions are again observed and recorded.
 Blind reading of test and control animals is
encouraged.
Rechallenge
 To clarify the results obtained in the first challenge, a
second challenge (i.e. a rechallenge), should be
considered approximately one week after the first
one.
 The rechallenge may also be performed on the
original control group.
Clinical observations
 All skin reactions
 Any unusual findings, including systemic reactions,
resulting from induction and challenge procedures
should be observed and recorded.
 to clarify doubtful reactions ,histopathological
examination, measurement of skin fold thickness,
may be carried out
DATA AND REPORTING (GPMT and Buehler
Test)
Data
 Data should be summarised in tabular form,
showing for each animal the skin reactions at each
observation.
Test report
 Test substance
 Vehicle
 Test animals
 Test conditions
 Reliability check
 Results
 Discussion of the results and reference substances.
Reference
 OECD (1992), Skin Sensitisation. OECD Guideline
for the Testing of Chemicals No 406, Paris, France.
Thank You

More Related Content

What's hot

test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies
SonaliJain736101
 
Female reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptxFemale reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptx
ashharnomani
 

What's hot (20)

Skin sensitisation (OECD: 406).
Skin sensitisation (OECD: 406).Skin sensitisation (OECD: 406).
Skin sensitisation (OECD: 406).
 
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
Female reproductive toxicity studies acoording to SECHDULE Y AND ICH S5R3
 
PPT On Female Reproductive Toxicology
PPT On Female Reproductive Toxicology PPT On Female Reproductive Toxicology
PPT On Female Reproductive Toxicology
 
test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies
 
Safety pharmacology
Safety pharmacologySafety pharmacology
Safety pharmacology
 
Reproductive toxicology studies
Reproductive toxicology studiesReproductive toxicology studies
Reproductive toxicology studies
 
Invivo Carcinogenecity Studies
Invivo Carcinogenecity StudiesInvivo Carcinogenecity Studies
Invivo Carcinogenecity Studies
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
Reproductive toxicology studies ACCORDING TO OECD guidlines 422
Reproductive toxicology  studies ACCORDING TO OECD guidlines 422 Reproductive toxicology  studies ACCORDING TO OECD guidlines 422
Reproductive toxicology studies ACCORDING TO OECD guidlines 422
 
Male and female reproductive toxicology
Male and female reproductive toxicologyMale and female reproductive toxicology
Male and female reproductive toxicology
 
Alternative methods to animal toxicity testing
Alternative methods to animal toxicity testingAlternative methods to animal toxicity testing
Alternative methods to animal toxicity testing
 
Safety pharmacology (siri)
Safety pharmacology (siri)Safety pharmacology (siri)
Safety pharmacology (siri)
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant Yadav
 
Ind enabling studies.
Ind enabling studies.Ind enabling studies.
Ind enabling studies.
 
Acute toxicity study for inhalation
Acute toxicity study for inhalationAcute toxicity study for inhalation
Acute toxicity study for inhalation
 
Female reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptxFemale reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptx
 
IND Enabling Studies (IND)
IND Enabling Studies  (IND)IND Enabling Studies  (IND)
IND Enabling Studies (IND)
 
Acute eye irritation test as per OECD guidelines
Acute eye irritation test as per OECD guidelinesAcute eye irritation test as per OECD guidelines
Acute eye irritation test as per OECD guidelines
 
Importance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingImportance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testing
 
skin sensitisation test
 skin sensitisation test skin sensitisation test
skin sensitisation test
 

Similar to Skin sensitization test (oecd 406)

dermal toxicity.pptx
dermal toxicity.pptxdermal toxicity.pptx
dermal toxicity.pptx
VaishnaviPatel76
 
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdfpharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
ManishJaat9
 

Similar to Skin sensitization test (oecd 406) (20)

Skin sensitisation, OECD Test guideline 406 .pptx
Skin sensitisation, OECD Test guideline 406 .pptxSkin sensitisation, OECD Test guideline 406 .pptx
Skin sensitisation, OECD Test guideline 406 .pptx
 
Expt. 10 Determination of acute skin irritation corrosion of a test substance
Expt. 10 Determination of acute skin irritation  corrosion of a test substanceExpt. 10 Determination of acute skin irritation  corrosion of a test substance
Expt. 10 Determination of acute skin irritation corrosion of a test substance
 
DERMAL IRRITATION STUDY ACCORDING TO OECD(404) GUIDELINES
DERMAL IRRITATION STUDY ACCORDING TO OECD(404) GUIDELINESDERMAL IRRITATION STUDY ACCORDING TO OECD(404) GUIDELINES
DERMAL IRRITATION STUDY ACCORDING TO OECD(404) GUIDELINES
 
dermal toxicity.pptx
dermal toxicity.pptxdermal toxicity.pptx
dermal toxicity.pptx
 
Dermal Irritation & corrosion PTSM ASHISH AG.pptx
Dermal Irritation & corrosion PTSM ASHISH AG.pptxDermal Irritation & corrosion PTSM ASHISH AG.pptx
Dermal Irritation & corrosion PTSM ASHISH AG.pptx
 
dermal irritation and dermal toxicity studies.pptx
dermal irritation and dermal toxicity studies.pptxdermal irritation and dermal toxicity studies.pptx
dermal irritation and dermal toxicity studies.pptx
 
OECD Dermal testing By Priya.pptx
OECD Dermal testing By Priya.pptxOECD Dermal testing By Priya.pptx
OECD Dermal testing By Priya.pptx
 
Invivo screening methods for anti inflammatory agents
Invivo screening methods for anti inflammatory  agentsInvivo screening methods for anti inflammatory  agents
Invivo screening methods for anti inflammatory agents
 
BioSafety merged projects e budget.pptx
BioSafety merged projects e budget.pptxBioSafety merged projects e budget.pptx
BioSafety merged projects e budget.pptx
 
Acute dermal irritation/corrosion: OECD 404
Acute dermal irritation/corrosion: OECD 404Acute dermal irritation/corrosion: OECD 404
Acute dermal irritation/corrosion: OECD 404
 
Acute eye irritation/corrosion- 405
Acute eye irritation/corrosion- 405Acute eye irritation/corrosion- 405
Acute eye irritation/corrosion- 405
 
Inflamation ppt
Inflamation pptInflamation ppt
Inflamation ppt
 
OECG Dermatotoxicity testing
OECG Dermatotoxicity testingOECG Dermatotoxicity testing
OECG Dermatotoxicity testing
 
acute dermal irritation .pptx
acute dermal irritation .pptxacute dermal irritation .pptx
acute dermal irritation .pptx
 
Acute Dermal Toxicity of synthesized polysaccharides according to OECD Guidel...
Acute Dermal Toxicity of synthesized polysaccharides according to OECD Guidel...Acute Dermal Toxicity of synthesized polysaccharides according to OECD Guidel...
Acute Dermal Toxicity of synthesized polysaccharides according to OECD Guidel...
 
Acute Eye Irritation\Corrosion toxicology studies
Acute Eye Irritation\Corrosion  toxicology studiesAcute Eye Irritation\Corrosion  toxicology studies
Acute Eye Irritation\Corrosion toxicology studies
 
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptxptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
 
In vitro alternatives for skin and eye irritation studies
In vitro alternatives for skin and eye irritation studiesIn vitro alternatives for skin and eye irritation studies
In vitro alternatives for skin and eye irritation studies
 
pharmacology practice school report.pptx
pharmacology practice school report.pptxpharmacology practice school report.pptx
pharmacology practice school report.pptx
 
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdfpharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
pharmacologypracticeschoolreport-221219060301-1ca27004 (1).pdf
 

Recently uploaded

ESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptxESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptx
muralinath2
 
Pests of sugarcane_Binomics_IPM_Dr.UPR.pdf
Pests of sugarcane_Binomics_IPM_Dr.UPR.pdfPests of sugarcane_Binomics_IPM_Dr.UPR.pdf
Pests of sugarcane_Binomics_IPM_Dr.UPR.pdf
PirithiRaju
 
Detectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a TechnosignatureDetectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a Technosignature
Sérgio Sacani
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
YOGESH DOGRA
 
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Sérgio Sacani
 
Aerodynamics. flippatterncn5tm5ttnj6nmnynyppt
Aerodynamics. flippatterncn5tm5ttnj6nmnynypptAerodynamics. flippatterncn5tm5ttnj6nmnynyppt
Aerodynamics. flippatterncn5tm5ttnj6nmnynyppt
sreddyrahul
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
muralinath2
 
THYROID-PARATHYROID medical surgical nursing
THYROID-PARATHYROID medical surgical nursingTHYROID-PARATHYROID medical surgical nursing
THYROID-PARATHYROID medical surgical nursing
Jocelyn Atis
 

Recently uploaded (20)

GEOLOGICAL FIELD REPORT On Kaptai Rangamati Road-Cut Section.pdf
GEOLOGICAL FIELD REPORT  On  Kaptai Rangamati Road-Cut Section.pdfGEOLOGICAL FIELD REPORT  On  Kaptai Rangamati Road-Cut Section.pdf
GEOLOGICAL FIELD REPORT On Kaptai Rangamati Road-Cut Section.pdf
 
SAMPLING.pptx for analystical chemistry sample techniques
SAMPLING.pptx for analystical chemistry sample techniquesSAMPLING.pptx for analystical chemistry sample techniques
SAMPLING.pptx for analystical chemistry sample techniques
 
ESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptxESR_factors_affect-clinic significance-Pathysiology.pptx
ESR_factors_affect-clinic significance-Pathysiology.pptx
 
Hemoglobin metabolism: C Kalyan & E. Muralinath
Hemoglobin metabolism: C Kalyan & E. MuralinathHemoglobin metabolism: C Kalyan & E. Muralinath
Hemoglobin metabolism: C Kalyan & E. Muralinath
 
Pests of sugarcane_Binomics_IPM_Dr.UPR.pdf
Pests of sugarcane_Binomics_IPM_Dr.UPR.pdfPests of sugarcane_Binomics_IPM_Dr.UPR.pdf
Pests of sugarcane_Binomics_IPM_Dr.UPR.pdf
 
insect taxonomy importance systematics and classification
insect taxonomy importance systematics and classificationinsect taxonomy importance systematics and classification
insect taxonomy importance systematics and classification
 
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
 
A Giant Impact Origin for the First Subduction on Earth
A Giant Impact Origin for the First Subduction on EarthA Giant Impact Origin for the First Subduction on Earth
A Giant Impact Origin for the First Subduction on Earth
 
Detectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a TechnosignatureDetectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a Technosignature
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
 
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
 
Aerodynamics. flippatterncn5tm5ttnj6nmnynyppt
Aerodynamics. flippatterncn5tm5ttnj6nmnynypptAerodynamics. flippatterncn5tm5ttnj6nmnynyppt
Aerodynamics. flippatterncn5tm5ttnj6nmnynyppt
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
 
EY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptxEY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptx
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
 
THYROID-PARATHYROID medical surgical nursing
THYROID-PARATHYROID medical surgical nursingTHYROID-PARATHYROID medical surgical nursing
THYROID-PARATHYROID medical surgical nursing
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
 

Skin sensitization test (oecd 406)

  • 1. HIMANSHU YADAV (201408006) M.PHARM (PHARMACOLOGY) SGT UNIVERSITY Skin sensitization toxicity studies
  • 2. Introduction  OECD Guidelines for Testing of Chemicals are periodically reviewed in light of scientific progress. This updated version of the original guideline 406, adopted in 1981, is the outcome of a meeting of OECD experts held in Paris in May 1991.  In updated version (17 Jul 1992) preference given to the guinea pig as an animal of choice for predictive sensitization tests for several decades.
  • 3. Types of Test Two types of tests have been developed: 1. Adjuvant tests in which sensitization is potentiated by the injection of Freunds Complete Adjuvant (FCA). 2. Non-adjuvant tests
  • 4. Types of Test  In the original guideline 406, 4 adjuvant tests and 3 non-adjuvant tests were considered.  In updated version, the Guinea Pig Maximization Test (GPMT) of Magnusson and Kligman which uses adjuvant (1)(2)(3)(4) and the non-adjuvant Buehler Test (5)(6) are given preference over other methods.
  • 5. Types of Test  Immune system of the mouse has been investigated more extensively than that of the guinea pig.  Advantages: short duration and minimal animal treatment  The mouse ear swelling test (MEST) and the local lymph node assay (LLNA) appear to be promising
  • 6. Types of Test  The LLNA or the MEST can be used as a first stage in the assessment of skin sensitization potential.  If a positive result is seen, a test substance may be designated as a potential sensitizer, and it may not be necessary to conduct a further guinea pig test.  If a negative result is seen in these test, a guinea pig test must be conducted.
  • 7. GENERAL PRINCIPLE OF SENSITISATION TESTS IN GUINEA PIGS  The test animals are initially exposed to the test substance by intradermal injection and/or epidermal application (induction exposure).  Following a rest period of 10 to 14 days (induction period), during which an immune response may develop, the animals are exposed to a challenge dose.  The extent and degree of skin reaction to the challenge exposure in the test animals is compared with that demonstrated by control animals which undergo sham treatment during induction and receive the challenge exposure
  • 8. ELEMENTS COMMON TO SENSITISATION TESTS IN GUINEA PIGS Sex of animals-Healthy Male /female .Females should be non-pregnant. Housing and feeding conditions  Temperature = 20 C (+ 3o C)  Relative humidity= 30-70%  Lighting is artificial= 12 hours light, 12 hours dark  Feeding= conventional diets with an unlimited drinking water.  It is essential that guinea pigs receive an adequate amount of ascorbic acid.
  • 9. Preparation of the animals  Acclimatization  Randomization  Assignment to the treatment groups  Clipping, shaving, chemical depilation  Weighing before the test commence
  • 10. Reliability check  Sensitivity of technique used should be assessed every six months by use of substances which are known to have mild-to-moderate skin sensitization properties A response of :  30% in an adjuvant test  15% in a non-adjuvant test should be expected for mild/moderate sensitizers  Preferred substances are hexyl cinnamic aldehyde (CAS No. 101-86-0), mercaptobenzothiazole (CAS No. 149-30-4) and benzocaine (CAS No. 94-09-7).
  • 11. Removal of the test substance  This should be achieved using water or an appropriate solvent without altering the existing response or the integrity of the epidermis
  • 12. GUINEA-PIG MAXIMISATION TEST METHOD Number of animals  Treatment group = Min. 10 animals  control group = 5 animals  When it is not possible to conclude that the test substance is a sensitizer, testing in additional animals to give a total of at least 20 test and 10 control animals is strongly recommended.
  • 13. Dose levels  The conc. of test substance used for each induction exposure should be well-tolerated systemically and should be the highest to cause mild-to-moderate skin irritation.  The conc. used for the challenge exposure should be the highest non-irritant dose.  The appropriate conc. can be determined from a pilot study using 2 or 3 animals. Consideration should be given to the use of FCA-treated animals for this purpose
  • 14. Induction: Intradermal Injections Day 0 - treated group  3 pairs of intradermal injections of 0.1 ml volume are given in the shoulder region which is cleared of hair so that one of each pair lies on each side of the midline.
  • 15. Induction: Intradermal Injections Day 0 - treated group Injection 1: a 1:1 mixture (v/v) FCA/water or physiological saline Injection 2: the test substance in an appropriate vehicle at the selected concentration Injection 3: the test substance at the selected concentration formulated in a 1:1 mixture (v/v) FCA/water or physiological saline.
  • 16. Induction: Intradermal Injections  In injection 3, water soluble substances are dissolved in the aqueous phase prior to mixing with FCA.  Liposoluble or insoluble substances are suspended in FCA prior to combining with the aqueous phase.  The concentration of test substance shall be equal to that used in injection 2.  Injections 1 and 2 are given close to each other and nearest the head, while 3 is given towards the caudal part of the test area
  • 17. Induction: Intradermal Injections Day 0 - control group  3 pairs of intradermal injections of 0.1 ml volume are given in the same sites as in the treated animals.
  • 18. Induction: Intradermal Injections Day 0 - control group Injection 1: a 1:1 mixture (v/v) FCA/water or physiological saline Injection 2: the undiluted vehicle Injection 3: a 50% w/v formulation of the vehicle in a 1:1 mixture (v/v) FCA/water or physiological saline
  • 19. Induction: Topical Application Day 5-7 - treated and control groups  24 hours before the topical induction application – The test area, after close-clipping or shaving is painted with 0.5 ml of 10% sodium lauryl sulphate in vaseline, to create a local irritation (if the substance is not a skin irritant).
  • 20. Induction: Topical Application Day 6-8 - treated group  The test area is again cleared of hair.  A filter paper (2 x 4 cm) is fully-loaded with test substance in a suitable vehicle and applied to the test area for 48 hours.  The choice of the vehicle should be justified.  Solids are finely pulverised and incorporated in a suitable vehicle.  Liquids can be applied undiluted, if appropriate.
  • 21. Challenge: Topical Application Day 20-22 - treated and control groups  The flanks of treated and control animals are cleared of hair.  A patch with the test substance is applied to one flank of the animals and, a patch with the vehicle only may also be applied to the other flank.  The patches are held in contact by an occlusive dressing for 24 hours.
  • 22. Observations - treated and control groups  Remove the patch after 21 hrs, the challenge area is cleaned and closely-clipped or shaved.  3 hours later (48 hours from the start of the challenge application) the skin reaction is observed  24 hours after this observation a second observation (72 hours) is made and once again recorded.  Blind reading of test and control animals is encouraged
  • 23. EVALUATION OF CHALLENGE PATCH TEST REACTIONS MAGNUSSON AND KLIGMAN GRADING SCALE  0 = no visible change  1 = discrete or patchy erythema  2 = moderate and confluent erythema  3 = intense erythema and swelling
  • 24. Rechallenge  If it is necessary to clarify the results obtained in the first challenge,  a second challenge (i.e. a rechallenge), where appropriate with a new control group, should be considered approximately one week after the first one.  A rechallenge may also be performed on the original control group.
  • 25. Clinical observations  All skin reactions and any unusual findings, including systemic reactions, resulting from induction and challenge procedures should be observed and recorded.  Other procedures, e.g histopathological examination, the measurement of skin fold thickness, may be carried out to clarify doubtful reactions
  • 26. THE BUEHLER TEST METHOD Number of animals  Treatment group- 20 animals  Control group- 10 animals Dose levels  The conc. of test substance for each induction exposure should be the highest to cause mild irritation.  The conc. used for the challenge exposure should be the highest non-irritating dose.  The appropriate conc. can be determined from a pilot study using two or three animals
  • 27. THE BUEHLER TEST METHOD  Water soluble test materials- water or a dilute non- irritating solution of surfactant as the vehicle.  For other test materials- 80% ethanol/water is preferred for induction and acetone for challenge
  • 28. Induction: Topical application Day 0 - treated group  One flank is cleared of hair (closely-clipped).  The test patch system should be fully loaded with test substance in a suitable vehicle ,held in contact with the skin for 6 hours.
  • 29. Induction: Topical application Day 0 - control group  One flank is cleared of hair (closely-clipped).  The vehicle only is applied in a similar manner to that used for the treated group.  The test patch system is held in contact with the skin for 6 hours.
  • 30. Induction: Topical application Days 6-8 and 13-15 - treated and control groups  The same application as on day 0 is carried out on the same test area (cleared of hair if necessary) of the same flank on day 6-8, and again on day 13-15
  • 31. Challenge Day 27-29 - treated and control groups  The untreated flank of treated and control animals is cleared of hair (closely-clipped).  An occlusive patch of test substance is applied, at the maximum non-irritant concentration, to the posterior untreated flank of treated and control animals  When relevant, an occlusive patch with vehicle only is also applied to the anterior untreated flank of both treated and control animals.  The patches are held in contact by a suitable dressing for 6 hours.
  • 32. Observations - treated and control groups  21 hours after removing the patch the challenge area is cleared of hair;  3 hrs later (i.e. 30 hrs after application of the challenge patch) the skin reactions are observed and recorded  24 hours after the 30 hour observation ( 54 hours after application of the challenge patch) skin reactions are again observed and recorded.  Blind reading of test and control animals is encouraged.
  • 33. Rechallenge  To clarify the results obtained in the first challenge, a second challenge (i.e. a rechallenge), should be considered approximately one week after the first one.  The rechallenge may also be performed on the original control group.
  • 34. Clinical observations  All skin reactions  Any unusual findings, including systemic reactions, resulting from induction and challenge procedures should be observed and recorded.  to clarify doubtful reactions ,histopathological examination, measurement of skin fold thickness, may be carried out
  • 35. DATA AND REPORTING (GPMT and Buehler Test) Data  Data should be summarised in tabular form, showing for each animal the skin reactions at each observation.
  • 36. Test report  Test substance  Vehicle  Test animals  Test conditions  Reliability check  Results  Discussion of the results and reference substances.
  • 37. Reference  OECD (1992), Skin Sensitisation. OECD Guideline for the Testing of Chemicals No 406, Paris, France.